Access the full text.
Sign up today, get DeepDyve free for 14 days.
P. Rossi, A. Machado, Michael Okun (2014)
Medicare coverage of investigational devices: the troubled path forward for deep brain stimulation.JAMA neurology, 71 5
Jonathan Darrow, J. Avorn, A. Kesselheim (2020)
FDA Approval and Regulation of Pharmaceuticals, 1983-2018.JAMA, 323 2
P. Rossi, J. Giordano, M. Okun (2017)
The Problem of Funding Off-label Deep Brain Stimulation: Bait-and-Switch Tactics and the Need for Policy Reform.JAMA neurology, 74 1
O. Faris, J. Shuren (2017)
An FDA Viewpoint on Unique Considerations for Medical-Device Clinical Trials.The New England journal of medicine, 376 14
J. Saviola (2005)
The FDA's role in medical device clinical studies of human subjectsJournal of Neural Engineering, 2
Rossi (2014)
Medicare coverage of investigational devices.JAMA Neurol, 71
Rossi (2017)
The problem of funding off-label deep brain stimulation.JAMA Neurol, 74
This Viewpoint posits that the regnant approval process for the use of neurotechnological devices to treat rare diseases is in need of reform.
JAMA Neurology – American Medical Association
Published: Jan 9, 2021
Read and print from thousands of top scholarly journals.
Already have an account? Log in
Bookmark this article. You can see your Bookmarks on your DeepDyve Library.
To save an article, log in first, or sign up for a DeepDyve account if you don’t already have one.
Copy and paste the desired citation format or use the link below to download a file formatted for EndNote
Access the full text.
Sign up today, get DeepDyve free for 14 days.
All DeepDyve websites use cookies to improve your online experience. They were placed on your computer when you launched this website. You can change your cookie settings through your browser.